Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

In this post hoc analysis we investigated the effects of insulin degludec/liraglutide fixed‐ratio combination (IDegLira) versus comparators on cardiovascular (CV) risk markers in participants in the DUAL II (vs. insulin degludec), DUAL V (vs. insulin glargine 100 units/mL) and DUAL VII (vs. basal–bo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Diabetes Obes Metab
Main Authors: Vilsbøll, Tina, Blevins, Thomas C., Jodar, Esteban, Poulter, Neil, Tentolouris, Nikolaos, Ross Agner, Bue F., Lehmann, Lucine, Leiter, Lawrence A.
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2019
Teme:
Brief Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6593827/
https://ncbi.nlm.nih.gov/pubmed/30785655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13675
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki